Dr. Janice Lansita joined PIC as Head of Toxicology Strategy responsible for overseeing the design and execution of the nonclinical toxicology studies.

Janice has over 19 years of experience, with previous roles at Biogen and with the Food and Drug Administration (FDA). As a regulatory toxicologist, she has developed small molecule and biologic therapies for oncology and other indications. Dr. Lansita has extensive experience in the design, monitoring, and interpretation of nonclinical toxicology studies (GLP and non-GLP) and has authored the nonclinical sections of various regulatory documents, including pre-INDs, INDs/CTAs (>50), Investigator Brochures, BLAs/NDAs, and package inserts/product labels for biopharmaceuticals. She has represented numerous clients with regulatory authority meetings (US and ex-US).

Janice received her Ph.D. from MIT in toxicology and her B.A. in biochemistry from Barnard College. She is a board-certified toxicologist.